Search
Cardiolipin Biosynthesis CL(a-13:0/i-24:0/a-13:0/a-13:0)[rac]
smpdb.ca/view/SMP0492113MetabolicLast, cardiolipin synthase catalyzes the synthesis of cardiolipin by transferring a phosphatidyl group from a second CDP-diacylglycerol to PG. It requires a divalent metal cation cofactor. … All membrane-localized enzymes are coloured dark green in the image.
Cardiolipin Biosynthesis CL(a-13:0/i-24:0/a-13:0/a-17:0)[rac]
smpdb.ca/view/SMP0492125MetabolicLast, cardiolipin synthase catalyzes the synthesis of cardiolipin by transferring a phosphatidyl group from a second CDP-diacylglycerol to PG. It requires a divalent metal cation cofactor. … All membrane-localized enzymes are coloured dark green in the image.
Cardiolipin Biosynthesis CL(a-13:0/i-24:0/a-15:0/a-13:0)[rac]
smpdb.ca/view/SMP0493235MetabolicLast, cardiolipin synthase catalyzes the synthesis of cardiolipin by transferring a phosphatidyl group from a second CDP-diacylglycerol to PG. It requires a divalent metal cation cofactor. … All membrane-localized enzymes are coloured dark green in the image.
Cardiolipin Biosynthesis CL(a-13:0/i-24:0/a-15:0/a-17:0)[rac]
smpdb.ca/view/SMP0493247MetabolicLast, cardiolipin synthase catalyzes the synthesis of cardiolipin by transferring a phosphatidyl group from a second CDP-diacylglycerol to PG. It requires a divalent metal cation cofactor. … All membrane-localized enzymes are coloured dark green in the image.
Cardiolipin Biosynthesis CL(a-13:0/i-24:0/a-17:0/a-21:0)[rac]
smpdb.ca/view/SMP0493355MetabolicLast, cardiolipin synthase catalyzes the synthesis of cardiolipin by transferring a phosphatidyl group from a second CDP-diacylglycerol to PG. It requires a divalent metal cation cofactor. … All membrane-localized enzymes are coloured dark green in the image.
Cardiolipin Biosynthesis CL(a-13:0/i-24:0/a-21:0/a-17:0)[rac]
smpdb.ca/view/SMP0493446MetabolicLast, cardiolipin synthase catalyzes the synthesis of cardiolipin by transferring a phosphatidyl group from a second CDP-diacylglycerol to PG. It requires a divalent metal cation cofactor. … All membrane-localized enzymes are coloured dark green in the image.
Cardiolipin Biosynthesis CL(a-13:0/i-24:0/a-25:0/a-13:0)[rac]
smpdb.ca/view/SMP0493544MetabolicLast, cardiolipin synthase catalyzes the synthesis of cardiolipin by transferring a phosphatidyl group from a second CDP-diacylglycerol to PG. It requires a divalent metal cation cofactor. … All membrane-localized enzymes are coloured dark green in the image.
Camizestrant
go.drugbank.com/drugs/DB19218ApprovedInvestigational[L64094,L64107] In pre- or peri-menopausal women and in men, camizestrant plus a CDK4/6 inhibitor is combined with an LHRH agonist or antagonist. … [L64117,L64107,L64116] It is the first next-generation oral SERD and complete ER antagonist approved in the first-line setting, and the only one approved for use with all three widely approved CDK4/6 inhibitors
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesSynonyms: 3-pyridinamine, n-(1-(3-fluoropropyl)-3-azetidinyl)-6-((6s,8r)-6,7,8,9-tetrahydro-8-methyl-7-(2,2,2-trifluoroethyl)-3h-pyrazolo(4,3-f)isoquinolin-6-yl)-, N-(1-(3-fluoropropyl)-3-azetidinyl)-6-((6s,8r)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3h-pyrazolo(4,3-f)isoquinolin-6-yl)-3-pyridinamineRizatriptan
go.drugbank.com/drugs/DB00953ApprovedInvestigationalRizatriptan is a second-generation triptan [A258918] and a selective 5-HT<sub>1B and 5-HT1D</sub> receptor agonist. … [L46018] Used in the treatment of migraines, rizatriptan was first approved in the US in 1998.
Categories: Monoamine Oxidase A Substrates, Heterocyclic Compounds, 1-RingSynonyms: N,N-Dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]-ethanamine, N,N-Dimethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-1H-indole-3-ethanamineCobimetinib
go.drugbank.com/drugs/DB05239ApprovedInvestigationalCobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction … It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment of patients with unresectable or metastatic BRAF V600 mutation-positive melanoma.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexProducts: COTELLIC® (COBIMETINIB) 20 MG TABLETAS RECUBIERTAS